Immune Cell Therapies and Immune Cell Engineering

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2⁺ patients with diffuse midline glioma
Lena Immisch, George Papafotiou, Oliver Popp, Philipp Mertins, Thomas Blankenstein, Gerald Willimsky

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005535; DOI: 10.1136/jitc-2022-005535
Autophagic flux restoration enhances the antitumor efficacy of tumor infiltrating lymphocytes
Chaoting Zhang, Yizhe Sun, Shance Li, Luyan Shen, Xia Teng, Yefei Xiao, Nan Wu, Zheming Lu

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e004868; DOI: 10.1136/jitc-2022-004868
Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells
Karen Kai-Lin Fang, Jongbok Lee, Ismat Khatri, Yoosu Na, Li Zhang

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007277; DOI: 10.1136/jitc-2023-007277
AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival
Vedika Mehra, Giulia Agliardi, Juliana Dias Alves Pinto, Manar S Shafat, Amaia Cadinanos Garai, Louisa Green, Alastair Hotblack, Fred Arce Vargas, Karl S Peggs, Anniek B van der Waart, Harry Dolstra, Martin A Pule, Claire Roddie

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007002; DOI: 10.1136/jitc-2023-007002
Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β
Demi Brownlie, Dahlia Doughty-Shenton, Daniel YH Soong, Colin Nixon, Neil O Carragher, Leo M Carlin, Takanori Kitamura

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e001740; DOI: 10.1136/jitc-2020-001740
Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy
Sophie M Poznanski, Tyrah M Ritchie, Isabella Y Fan, Abdullah El-Sayes, Ana L Portillo, Ronny Ben-Avi, Eduardo A Rojas, Marianne V Chew, Yaron Shargall, Ali A Ashkar

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e001933; DOI: 10.1136/jitc-2020-001933
Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy
Anastasia Prokopi, Christoph H Tripp, Bart Tummers, Florian Hornsteiner, Sarah Spoeck, Jeremy Chase Crawford, Derek R Clements, Mirjana Efremova, Katharina Hutter, Lydia Bellmann, Giuseppe Cappellano, Bruno L Cadilha, Sebastian Kobold, Louis Boon, Daniela Ortner, Zlatko Trajanoski, Suzie Chen, Tanja D de Gruijl, Juliana Idoyaga, Douglas R Green, Patrizia Stoitzner

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e000832; DOI: 10.1136/jitc-2020-000832
Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment
Dan Liu, Xiyue Xu, Yulian Dai, Xuan Zhao, Shunshun Bao, Wen Ma, Li Zha, Shuci Liu, Yuchen Liu, Junnian Zheng, Ming Shi

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e001466; DOI: 10.1136/jitc-2020-001466
Deletion of Cbl-b inhibits CD8⁺ T-cell exhaustion and promotes CAR T-cell function
Jitendra Kumar, Ritesh Kumar, Amir Kumar Singh, Elviche L Tsakem, Mahesh Kathania, Matthew J Riese, Arianne L Theiss, Marco L Davila, K Venuprasad

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e001688; DOI: 10.1136/jitc-2020-001688
Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
Tsung-Yi Lin, Jeong A Park, Alan Long, Hong-Fen Guo, Nai-Kong V Cheung

Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) e003114; DOI: 10.1136/jitc-2021-003114

Main menu

Immune Cell Therapies and Immune Cell Engineering

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immune Cell Therapies and Immune Cell Engineering

Pages